-
Patent Agency Ranking
公开(公告)号：US11202808B2
公开(公告)日：2021-12-21
申请号：US16235635
申请日：2018-12-28
Applicant: Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Finch Therapeutics Holdings LLC
Inventor： James Adams , Rosa Krajmalnik-Brown , Dae-Wook Kang , Michael J. Sadowsky , Alexander Khoruts , Thomas J. Borody
Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US11357801B2
公开(公告)日：2022-06-14
申请号：US16306240
申请日：2017-06-14
Inventor： James Adams , Dae-Wook Kang , Rosa Krajmalnik-Brown
IPC: A61K35/741 , A61K35/745 , A61K35/74
Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.
-
公开(公告)号：US20250027172A1
公开(公告)日：2025-01-23
申请号：US18807794
申请日：2024-08-16
Inventor： Rosa Krajmalnik-Brown , Dae-Wook Kang , Jin Gyoon Park , Joshua Labaer , Zehra IIhan
IPC: C12Q1/689 , A61K31/437 , A61K35/741 , C12Q1/6883 , G01N33/68
Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.
-
公开(公告)号：US12084727B2
公开(公告)日：2024-09-10
申请号：US18147224
申请日：2022-12-28
Inventor： Rosa Krajmalnik-Brown , Dae-Wook Kang , Jin Gyoon Park , Joshua Labaer , Zehra IIhan
IPC: C12Q1/689 , A61K31/437 , A61K35/741 , C12Q1/6883 , G01N33/68
CPC classification number: C12Q1/689 , A61K31/437 , A61K35/741 , C12Q1/6883 , G01N33/6896 , C12Q2600/142 , C12Q2600/158
Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.
-
公开(公告)号：US20230220494A1
公开(公告)日：2023-07-13
申请号：US18147224
申请日：2022-12-28
Inventor： Rosa Krajmalnik-Brown , Dae-Wook Kang , Jin Gyoon Park , Joshua Labaer , Zehra IIhan
IPC: C12Q1/689 , G01N33/68 , C12Q1/6883 , A61K31/437 , A61K35/741
CPC classification number: C12Q1/689 , G01N33/6896 , C12Q1/6883 , A61K31/437 , A61K35/741 , C12Q2600/142 , C12Q2600/158
Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.
-
-
-
-
Search Results
5
records
(took 0.02 seconds)
